Kailera Therapeutics (NASDAQ:KLRA) Reaches New 12-Month Low – Time to Sell?

Kailera Therapeutics, Inc. (NASDAQ:KLRA) reached a new 52-week low during mid-day trading on Friday . The stock traded as low as $18.69 and last traded at $18.83, with a volume of 260824 shares. The stock had previously closed at $19.54.

Analysts Set New Price Targets

Several research firms have weighed in on KLRA. Zacks Research raised Kailera Therapeutics to a “hold” rating in a research note on Wednesday, May 13th. Jefferies Financial Group assumed coverage on Kailera Therapeutics in a research note on Tuesday, May 12th. They issued a “buy” rating and a $48.00 price target for the company. TD Cowen assumed coverage on Kailera Therapeutics in a research note on Tuesday, May 12th. They issued a “buy” rating and a $57.00 price target for the company. Wall Street Zen cut Kailera Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 30th. Finally, JPMorgan Chase & Co. assumed coverage on Kailera Therapeutics in a research note on Tuesday, May 12th. They issued an “overweight” rating and a $30.00 price target for the company. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $42.75.

Kailera Therapeutics Trading Down 3.3%

Insider Transactions at Kailera Therapeutics

In other Kailera Therapeutics news, Director Andrew T. Kaplan purchased 8,398,438 shares of the business’s stock in a transaction dated Monday, April 20th. The stock was bought at an average cost of $16.00 per share, for a total transaction of $134,375,008.00. Following the completion of the acquisition, the director directly owned 26,255,581 shares in the company, valued at $420,089,296. This represents a 47.03% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Rtw Investments, Lp purchased 500,000 shares of the business’s stock in a transaction dated Monday, April 20th. The shares were acquired at an average price of $16.00 per share, with a total value of $8,000,000.00. Following the completion of the acquisition, the insider owned 10,776,820 shares of the company’s stock, valued at approximately $172,429,120. The trade was a 4.87% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders acquired a total of 10,460,938 shares of company stock worth $167,375,008 over the last three months.

About Kailera Therapeutics

We are an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care by advancing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey. Obesity is a chronic, progressive and debilitating disease that impacts over 1 billion people globally and requires long-term comprehensive treatment. Since obesity is the driving factor for more than 200 comorbidities and represents a significant contributor to increased morbidity and mortality, our vision is to deliver category-leading obesity management medications that give people the power to restore their health and transform their lives.